Prices, profits, budgets, production and policy: the news that moves Pakistan’s pharmaceutical industry.
Prices of non-essential medicines were freed in February 2024. Officials now report over 99% availability, while the pricing framework faces a fresh review.
Listed drug makers earned Rs42.2 billion in FY26 on sales of Rs377.9 billion, with gross margins at an all-time high of 42.8%.
The Finance Minister announced the full removal of customs duty on raw materials for locally made medicines, including cancer treatments.
Official figures show a hard year for production and exports — and an ambitious roadmap to $10 billion in exports built on value addition.
